(Axios) – A divided House of Representatives on Wednesday endorsed banning quality-adjusted life years from being used as a metric for determining a drug’s value in federal health programs. Why it matters: QALYs are viewed as a key tool in comparative effectiveness studies, but have been held up as discriminatory against people with disabilities — and are unevenly applied across federal programs. (Read More)